ArticleEuropean journal of medical research2025
Sestrin2 ameliorates LPS-induced cardiomyocyte injury by inhibiting ferroptosis via the Nrf2/HO-1 pathway.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Parthenolide inhibits the progression of intrahepatic cholangiocarcinoma by promoting ferroptosis through inhibiting UBD.Cancer biology & therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe pathogenesis of sepsis-induced myocardial injury is complex. Currently, treatment for this disease remains suboptimal. Sestrin2 (Sesn2) is an antioxidant protein and has been shown to have a protective role in some diseases. However, its role in sepsis-induced cardiomyocyte injury has not been fully elucidated.
methodsAn in vitro model of sepsis-induced myocardial injury was established by treating H9c2 cardiomyocytes with lipopolysaccharide (LPS). The viability of H9c2 cardiomyocytes was quantified using the cell counting kit-8. Protein expression levels were analyzed by Western blotting. Apoptosis and mitochondrial membrane potential were quantified by flow cytometry. Mitochondrial ultrastructure was observed by transmission electron microscopy. Malondialdehyde (MDA), superoxide dismutase (SOD), reduced glutathione (GSH), reactive oxygen species (ROS), and iron content were quantified using commercial assay kits. The ferroptosis inducer Erastin was employed to further investigate the role of Sesn2 in ferroptosis. The potential regulatory relationship between Sesn2 and the Nrf2/HO-1 pathway was investigated using the Nrf2 inhibitor ML385.
resultsSesn2 overexpression significantly improved cell viability, ameliorated mitochondrial damage, upregulated GPX4 and SLC7A11 expression, downregulated ACSL4 expression, reduced MDA and Fe
conclusionsThis study demonstrates that Sesn2 inhibits ferroptosis in LPS-treated H9c2 cells through the Nrf2/HO-1 pathway, and also exerts an anti-apoptotic effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.